Abstract
In this manuscript we argue that the use of Sofosbuvir as a possible medication in the clinical treatment of COVID-19 can be complemented with HCV protease inhibitors given the homology between the HCV NS3/4A protease and the SARS-CoV-2 Mpro protease.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
